Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic to Help H. Lundbeck Reposition, Develop Shelved Drug Candidates

NEW YORK (GenomeWeb News) — Gene Logic yesterday said it will help H. Lundbeck reposition and develop certain drugs candidates that were “discontinued” or “de-prioritized” for reasons other than safety.
 
Gene Logic said the deal allows for milestones and royalties similar to those paid for development-stage in-licensing deals, discounted to account for Lundbeck's contribution as the originator of the compound.
 
It also provides an option to license any of the candidates that Lundbeck decides not to pursue, in which case Lundbeck would receive success-based milestone and royalty payments.
 
Financial details were not disclosed.
 
Gene Logic also said yesterday that it expects to pocket around $2.5 million from Lundbeck over the coming year from an unrelated technology licensing agreement.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.